ファジルシランの安全性と、軽度の肝瘢痕(線維症)を伴うα-1アンチトリプシン肝疾患患者を助けることができるかどうかを学ぶ研究
METAVIR ステージ F1 線維症を伴うα-1 アンチトリプシン欠乏症関連肝疾患の治療におけるファジルシランの安全性と有効性を評価する無作為化二重盲検プラセボ対照第 3 相試験
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually end stage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver.
People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran, whether participants tolerate the treatment and if there are any effects on liver scarring. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study.
After their last clinic visits, participants will have two choices:
- They can complete this study and return to the clinic 3 and 6 months later so the study doctors can check for side effects; OR
- If they meet the rules, they can join another study (called extension or continuation study), in which they will receive fazirsiran every 3 months and will continue to have health checks.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Takeda Contact
- 電話番号:+1-877-825-3327
- メール:medinfoUS@takeda.com
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85013-4224
- 募集
- St Joseph's Hospital and Medical Center
-
主任研究者:
- Justin Reynolds
-
コンタクト:
- Site Contact
- 電話番号:602-274-7195
-
Phoenix、Arizona、アメリカ、85054-4502
- 募集
- Mayo Clinic - PPDS
-
主任研究者:
- Hugo Vargas
-
コンタクト:
- Site Contact
- 電話番号:480-301-6990
- メール:vargas.hugo@mayo.edu
-
Tucson、Arizona、アメリカ、85724-0001
- 募集
- University of Arizona Thomas D. Boyer Liver Institute
-
コンタクト:
- Site Contact
- 電話番号:520-626-3005
- メール:gdblock@deptofmed.arizona.edu
-
主任研究者:
- Geoffrey Block
-
-
California
-
La Jolla、California、アメリカ、92037-1337
- 募集
- University of California San Diego
-
主任研究者:
- Rohit Loomba
-
コンタクト:
- Site Contact
- 電話番号:858-534-2555
- メール:roloomba@health.ucsd.edu
-
Los Angeles、California、アメリカ、90095-3075
- 募集
- UCLA Pulmonary and Critical Care
-
主任研究者:
- Igor Barjaktarevic
-
コンタクト:
- Site Contact
- 電話番号:310-825-8061
-
San Francisco、California、アメリカ、94143-2203
- 募集
- University of California Benioff Children's Hospital
-
主任研究者:
- Philip Rosenthal
-
コンタクト:
- Site Contact
- 電話番号:415-476-5892
- メール:PROSENTH@ucsf.edu
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80907
- 募集
- Peak Gastroenterology Associates
-
主任研究者:
- Bhaktasharan Patel
-
コンタクト:
- Site Contact
- 電話番号:719-636-1201
-
-
Florida
-
Miami、Florida、アメリカ、33136
- 募集
- Schiff Center for Liver Diseases/University of Miami
-
主任研究者:
- Eugene Schiff
-
コンタクト:
- Site Contact
- 電話番号:305-243-5185
- メール:idsresearch@med.miami.edu
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202-2266
- 募集
- Indiana University School of Medicine-Indianapolis
-
主任研究者:
- Raj Vuppalanchi
-
コンタクト:
- Site Contact
- 電話番号:317-278-4607
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242-1009
- 募集
- University Of Iowa Hospitals And Clinics
-
主任研究者:
- Tomohiro Tanaka
-
コンタクト:
- Site Contact
- 電話番号:319-356-2577
- メール:Tomohiro-tanaka@uiowa.edu
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02118-2335
- 募集
- Boston Medical Center
-
主任研究者:
- Arpan Mohanty
-
コンタクト:
- Site Contact
- 電話番号:617-638-6525
- メール:arpan.mohanty@bmc.org
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan Hospital - 1500 E Medical Center Dr
-
主任研究者:
- Robert Fontana
-
コンタクト:
- Site Contact
- 電話番号:734-232-3741
-
Novi、Michigan、アメリカ、48377-3600
- 募集
- Henry Ford Health System
-
主任研究者:
- Stuart Gordon
-
コンタクト:
- Site Contact
- 電話番号:248-344-6688
- メール:sgordon3@hfhs.org
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic PPDS
-
主任研究者:
- Harmeet Malhi
-
コンタクト:
- Site Contact
- 電話番号:507-284-0141
-
-
New York
-
New York、New York、アメリカ、10016-6402
- 募集
- NYU Langone Medical Center
-
主任研究者:
- Viviana Figueroa Diaz
-
コンタクト:
- Site Contact
- 電話番号:212-263-3643
- メール:viviana.figueroadiaz@nyumc.org
-
New York、New York、アメリカ、10032-3722
- 募集
- Columbia University Irving Medical Center
-
主任研究者:
- Monica Goldklang
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106-1716
- 募集
- University Hospitals Cleveland Medical Center
-
主任研究者:
- Seth Sclair
-
コンタクト:
- Site Contact
- 電話番号:216-983-0879
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033-2360
- 募集
- Penn State Health Milton S. Hershey Medical Center
-
主任研究者:
- Timothy Craig
-
コンタクト:
- Site Contact
- 電話番号:717-531-7532
- メール:tcraig@pennstatehealth.psu.edu
-
-
Texas
-
San Antonio、Texas、アメリカ、78215
- 募集
- Texas Liver Institute American Research Corporation
-
主任研究者:
- Eric Lawitz
-
コンタクト:
- Site Contact
- 電話番号:210-253-3426
- メール:lawitz@txliver.com
-
-
Virginia
-
Newport、Virginia、アメリカ、23602-4414
- 募集
- Bon Secours St. Mary's Hospital
-
コンタクト:
- Site Contact
- 電話番号:804-977-8920
- メール:mitchell_shiffman@bshsi.org
-
主任研究者:
- Mitchell Schiffman
-
-
-
-
-
London、イギリス、SE5 9RS
- 募集
- King's College Hospital
-
主任研究者:
- Aftab Ala
-
コンタクト:
- Site Contact
- 電話番号:+442032993506
-
-
-
-
-
Pavia、イタリア、27100
- 募集
- Fondazione IRCCS Policlinico San Matteo
-
主任研究者:
- Angelo Corsico
-
コンタクト:
- Site Contact
- 電話番号:+390382503777
-
-
-
-
-
Graz、オーストリア、8036
- 募集
- LKH-Universitätsklinikum Graz
-
コンタクト:
- Site Contact
- 電話番号:+4331638580287
- メール:martin.wagner@medunigraz.at
-
主任研究者:
- Martin Wagner
-
Klagenfurt、オーストリア、9020
- 募集
- KABEG - Klinikum Klagenfurt Am Wörthersee
-
主任研究者:
- Markus Peck-Radosavljevic
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5T 3A9
- 募集
- Inspiration Research Limited
-
主任研究者:
- Kenneth Chapman
-
コンタクト:
- Site Contact
- 電話番号:(416) 944-9602
-
-
-
-
-
Bern、スイス、3010
- 募集
- Universitätsspital Bern
-
主任研究者:
- Guido Stirnimann
-
コンタクト:
- Site Contact
- 電話番号:+41442663568
-
-
-
-
-
Huddinge、スウェーデン、14186
- 募集
- Karolinska Universitetssjukhuset Huddinge
-
コンタクト:
- Site Contact
- 電話番号:+46858580000
-
主任研究者:
- Staffan Wahlin
-
-
-
-
-
Seville、スペイン、41018
- 募集
- Hospital Universitario Virgen del Rocio - PPDS
-
コンタクト:
- Site Contact
- 電話番号:+34955012065
- メール:mromerogomez@us.es
-
主任研究者:
- Manuel Romero Gómez
-
-
-
-
-
Aachen、ドイツ、52074
- 募集
- Universitätsklinikum der RWTH Aachen
-
主任研究者:
- Pavel Strnad
-
コンタクト:
- 電話番号:+492418035324
- メール:pstrnad@ukaachen.de
-
Berlin、ドイツ、13353
- 募集
- Charité - Campus Virchow-Klinikum
-
コンタクト:
- Site Contact
- 電話番号:+4939450553022
- メール:frank.tacke@charite.de
-
主任研究者:
- Frank Tacke
-
Hanover、ドイツ、30625
- 募集
- Hannover Medical School
-
主任研究者:
- Heiner Wedemeyer
-
コンタクト:
- Site Contact
- 電話番号:+495115322730
-
Tübingen、ドイツ、72076
- 募集
- Universitätsklinikum Tübingen
-
主任研究者:
- Christoph Berg
-
コンタクト:
- Site Contact
- 電話番号:+4970712977661
-
-
-
-
-
Lyon、フランス、69317
- 募集
- Hôpital de La Croix Rousse
-
コンタクト:
- Site contact
- 電話番号:+33145596790
- メール:teresa.antonini@aphp.fr
-
主任研究者:
- Teresa Antonini
-
Rennes、フランス、35000
- 募集
- Hopital PONTCHAILLOU CHU de Rennes
-
コンタクト:
- Site Contact
- 電話番号:+33299284297
- メール:edouard.bardou-jacquet@chu-rennes.fr
-
主任研究者:
- Edouard Bardou-Jacquet
-
Val-de-Marne、フランス、94800
- 募集
- Hôpital Paul Brousse
-
コンタクト:
- Site Contact
- 電話番号:+33145593336
- メール:audrey.coilly@aphp.fr
-
主任研究者:
- Audrey Coilly
-
-
-
-
-
Antwerp、ベルギー、2650
- 募集
- UZ Antwerpen
-
主任研究者:
- Sven Francque
-
コンタクト:
- Site Contact
- 電話番号:+3238213323
- メール:sven.francque@uza.be
-
Leuven、ベルギー、3000
- 募集
- UZ Leuven
-
主任研究者:
- Jef Verbeek
-
コンタクト:
- Site Contact
- 電話番号:+328888888888
- メール:jef.verbeek@uzleuven.be
-
-
-
-
-
Braga、ポルトガル、4710-243
- 募集
- CCA Hospital Braga
-
主任研究者:
- Carla Rolanda
-
Funchal、ポルトガル、9000-168
- 募集
- Hospital Dr. Nélio Mendonça
-
主任研究者:
- Vitor Pereira
-
コンタクト:
- Site Contact
- 電話番号:(351) 291-7056 x00
-
Porto、ポルトガル、4099-001
- 募集
- Centro Hospitalar de Universitário de Santo António E.P.E
-
コンタクト:
- Site Contact
- 電話番号:+351918000000
-
主任研究者:
- Luís Maia
-
-
-
-
-
Mysłowice、ポーランド、41-400
- 引きこもった
- ID Clinic Arkadiusz Pisula
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- In the opinion of the investigator, the participant is capable of understanding and fully complying with the protocol requirements and adhering to the protocol schedule.
- The participant is able to read, understand, and complete the study questionnaires electronically per the investigator's judgment.
- The participant signs and dates a written Informed Consent Form (ICF). Any required privacy authorization should also be signed before the initiation of any study procedures.
- The participant, of any sex, is aged 18 to 75 years, inclusive.
- The participant must have a diagnosis of the protease inhibitor Z mutation (PiZZ) genotype AATD. A diagnosis of PiZZ from source-verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted.
- The participant's liver biopsy core samples collected as per protocol requirements.
- The participant has evidence of METAVIR stage F1 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading from a previous biopsy conducted within 1 year before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual.
- The participant has a pulmonary status that meets the protocol requirements.
- It must be confirmed that the participant does not have hepatocellular carcinoma (HCC).
- Any participant who is taking statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or beta-1 selective adrenergic receptor inhibitors must have been receiving a stable dose of these medications for at least 8 weeks before randomization. All attempts are to be made for the participant to continue the same dose of the medication for the duration of study participation.
- An adult participant must have a body mass index (BMI) greater than or equal to (>=) 18 kilogram per meter square (kg/m^2).
- The participant has a 12-lead electrocardiogram at screening that, in the opinion of the investigator, has no abnormalities that could compromise the participant's safety in this study.
- The participant is a nonsmoker.
- If the participant was being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose systemic corticosteroids (prednisone less than or equal to [<=10] milligrams per day [mg/d] or its equivalent), the doses of the participant's medications must have remained unchanged for >=4 weeks before screening.
- The participant must have suitable venous access for blood sampling.
- A person of childbearing potential (POCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 before dosing.
- The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study and for 6 months after the last dose of study medication. The participant must not donate sperm for at least 6 months after the last dose of study medication.
Exclusion criteria:
- The participant has evidence of >= F2 fibrosis based on liver biopsy during the screening period.
- The participant has a history of liver decompensating events.
- The participant has a history of varices based on a previous esophagogastroduodenoscopy.
- The participant has portal vein thrombosis.
- The participant has undergone a prior trans-jugular portosystemic shunt procedure.
- The participant has evidence of other forms of chronic liver diseases.
- The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with curatively treated malignancies who have no evidence of metastatic disease and disease-free interval greater than (>) 1 year may be enrolled. Individual cases may be discussed with the medical monitor for guidance.
- The participant has an abnormal finding of clinical relevance at the screening evaluation and before administration of the first dose of study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results.
- The participant has any laboratory abnormalities at screening and before the first dose of the study drug that meet protocol parameters.
- The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals.
- The participant has a recent lower respiratory tract infection, such as pneumonia, within the last 6 months prior to screening, unless, in the opinion of the investigator, the participant has achieved clinical recovery with pulmonary function returned to baseline. Individual cases may be discussed with the medical monitor for guidance.
- The participant has a history of frequent pulmonary exacerbations (>=2 moderate or severe exacerbations within 52 weeks before screening).
- The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be rescreened after the clinical resolution of an exacerbation).
- The participant is receiving long-term, around-the-clock oxygen supplementation or supplemental oxygen with continuous positive airway pressure (CPAP) or bilevel positive airway pressure for acute respiratory failure. The following conditions are allowable for the participant to enter screening: short-term use of oxygen supplementation (example, for the management of acute chronic obstructive pulmonary disease [COPD] exacerbation) or CPAP for obstructive sleep apnea.
- The participant has human immunodeficiency virus (HIV) infection as shown by the presence of anti-HIV antibody (seropositive).
- The participant is seropositive for hepatitis B virus (HBV surface antigen positive and/or HBV core antibody positive without HBV surface antibody at screening) or hepatitis C virus (HCV) (detectable HCV Ribonucleic Acid [RNA] at screening). Cured HCV (positive antibody test without detectable HCV RNA for at least 6 months after treatment) is acceptable.
- The participant has unstable, poorly controlled, or severe hypertension. Participants may be rescreened once their blood pressure (BP) is successfully controlled.
- The participant has a history of ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if they participate in the study, in the opinion of the investigator. Examples of significant ECG abnormalities include: torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia), heart block (excluding first-degree block, being PR interval prolongation only), congenital long QT syndrome or new ST-segment elevation or depression or a new Q wave on ECG.
- The participant has symptomatic heart failure (per New York Heart Association guidelines), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction less than [<] 20 percent [%]), transient ischemic attack, or cerebrovascular accident within 6 months before screening.
- The participant has a history of major surgery within 12 weeks of screening (or longer, at the discretion of the investigator).
- The participant has a history of more than moderate alcohol consumption within 12 months before the screening visit.
- The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening.
- The participant has previously been treated with fazirsiran or any other RNA interference (RNAi) for alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).
- The participant has a history of hypersensitivity or allergies with any associated excipients of fazirsiran.
- The participant has received an investigational agent or device within 30 days, or 5 half-lives, whichever is longer, before the dosing of study medication or is currently participating in an investigational study involving a therapeutic intervention.
- The participant has donated >=500 milliliter (mL) of blood within 1 month of the administration of study treatment.
- The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk. The participant has a history of clinically significant hematologic, renal, hepatic, pulmonary, neurologic, psychiatric, gastrointestinal (GI), systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
- The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 6 months before screening, or is taking chronic anticoagulants.
- This participant is unable to return for all scheduled study visits.
- The participant has symptomatic confirmed coronavirus disease 2019 (COVID-19) that, in the opinion of the investigator, does not resolve during screening; however, enrollment may be temporarily delayed at the discretion of the investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation. Individual cases may be discussed with the medical monitor for guidance.
- The participant is a study site employee involved in the conduct of this study, an immediate family member (example, spouse, parent, child, sibling), is in a dependent relationship with study site employee who is involved in the conduct of this study or may consent under duress.
- The participant takes or is required to take excluded medications.
- The participant is pregnant or breastfeeding or intending to become pregnant before participating in this study, during the study, or within 6 months after last dose of the study drug; or the participant is intending to donate ova during such time period.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Fazirsiran 200 mg
Participants will receive fazirsiran 200 milligrams (mg), injection, subcutaneously on Day 1, at Week 4 and then every 12 weeks (Q12W) for up to Week 100. |
Fazirsiran will be injected subcutaneously.
他の名前:
|
|
プラセボコンパレーター:Placebo
Participants will receive fazirsiran matching placebo injection, subcutaneously on Day 1, at Week 4 and Q12W for up to Week 100. |
Fazirsiran matching placebo. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
時間枠:From start of study drug administration up to end of study (EOS) (Week 124)
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not it is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study intervention. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, suspected transmission of any infectious agent, an important medical event. AEs and SAEs including any pulmonary AEs or SAEs indicative of worsening pulmonary condition (example, pulmonary exacerbation, respiratory infection, significant pulmonary function test decline) will be reported. |
From start of study drug administration up to end of study (EOS) (Week 124)
|
|
Number of Participants With Clinically Significant Change From Baseline in Pulmonary Function Parameters
時間枠:From start of study drug administration up to EOS (Week 124)
|
Standard pulmonary function parameters will be used to study lung function. Clinical significance of pulmonary function parameters will be determined at the investigator's discretion. |
From start of study drug administration up to EOS (Week 124)
|
|
Change From Baseline in Whole Lung 15th Percentile Density as Measured by Computed Tomography (CT) Lung Densitometry
時間枠:Baseline up to Week 100
|
Change from baseline in whole lung 15th percentile density as measured by CT lung densitometry will be assessed. |
Baseline up to Week 100
|
|
Number of Participants With Clinically Significant Changes in Vital Signs
時間枠:From start of study drug administration up to EOS (Week 124)
|
Vital signs include body temperature, respiratory rate, blood pressure (systolic and diastolic), pulse (beats per minute) and pulse oximetry. Clinical significance of vital signs will be determined at the investigator's discretion. |
From start of study drug administration up to EOS (Week 124)
|
|
Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Parameters
時間枠:From start of study drug administration up to EOS (Week 124)
|
12-lead ECG will be evaluated. Any clinically significant change in ECG assessments will be determined at the investigator's discretion. |
From start of study drug administration up to EOS (Week 124)
|
|
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
時間枠:From start of study drug administration up to EOS (Week 124)
|
Laboratory parameters assessments include hematology, biochemistry including liver tests, coagulation, and urinalysis. Clinical significance of laboratory parameters will be determined at the investigator's discretion. |
From start of study drug administration up to EOS (Week 124)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Serum Z-AAT Protein Over Time to Week 106
時間枠:Baseline up to Week 106
|
Change From Baseline in Serum Z-AAT Protein will be assessed. |
Baseline up to Week 106
|
|
Percent Change From Baseline in Intrahepatic Liver Z-AAT Protein at Week 106
時間枠:Baseline up to Week 106
|
Percent change from baseline in intrahepatic liver Z-AAT protein will be assessed. |
Baseline up to Week 106
|
|
Change From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 106
時間枠:Baseline up to Week 106
|
Change from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining in liver biopsy will be assessed. |
Baseline up to Week 106
|
|
Number of Participants with No Change or Decrease From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by PAS+D Staining at Week 106
時間枠:Baseline up to Week 106
|
Number of participants with no change or decrease from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining will be reported. |
Baseline up to Week 106
|
|
Change From Baseline in Intrahepatic Portal Inflammation Score in Liver Biopsy at Week 106
時間枠:Baseline up to Week 106
|
Change in portal inflammation score in liver biopsy is based on pathology slide reads. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation. |
Baseline up to Week 106
|
|
Number of Participants with No Change or Decrease From Baseline in Intrahepatic Portal Inflammation Score at Week 106
時間枠:Baseline up to Week 106
|
No Change or decrease in portal inflammation score is based on pathology slide reads. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation. Number of Participants with no change or decrease from baseline in intrahepatic portal inflammation score will be reported. |
Baseline up to Week 106
|
|
Number of Participants With No Change or Decrease From Baseline in Histologic Fibrosis Score (Meta-analysis of Histological Data in Viral Hepatitis [METAVIR] Staging) at Week 106
時間枠:Baseline up to Week 106
|
No change or decrease in histologic fibrosis (METAVIR staging) will be assessed using a fibrosis score of F0-F4, where higher scores mean a worse result. Number of participants with no change or decrease from baseline in histologic fibrosis score (by [METAVIR] staging) at Week 106 will be reported. |
Baseline up to Week 106
|
|
Change From Baseline in Vibration-Controlled Transient Elastography (VCTE)-Derived Liver Stiffness
時間枠:Baseline up to Week 106
|
Change from baseline in VCTE-derived liver stiffness will be assessed. |
Baseline up to Week 106
|
|
Change From Baseline in Markers of Liver Injury
時間枠:Baseline up to Week 106
|
Change from baseline in marker (alanine aminotransferase [ALT], aspartate aminotransferase [AST], glutamyl transferase [GGT]) of liver injury will be assessed. |
Baseline up to Week 106
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Study Director、Takeda
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- TAK-999-3002
- 2023-504198-19-00 (Ctis:EU CTIS)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD 共有アクセス基準
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。